|Dr. Maria Palasis Ph.D.||Chair of the Board, CEO & Pres||754.07k||N/A||1965|
|Mr. R. Donald Elsey||CFO, Treasurer & Sec.||536.34k||N/A||1954|
|Dr. Robert Richard Ph.D.||Sr. VP of R&D||366.74k||N/A||1957|
|Dr. Carmichael S. Roberts Jr.||Co-Founder||N/A||N/A||1969|
|Mr. Ray Knox||VP of Operations||N/A||N/A||N/A|
|Ms. Corinne Noyes||Sr. VP of Commercial Strategy & Market Devel.||N/A||N/A||1968|
|Ms. Vineeta Belanger Ph.D.||Sr. VP of Clinical Affairs||N/A||N/A||N/A|
|Ms. Pamela E. Nelson||Sr. VP of Regulatory Affairs||N/A||N/A||1970|
|Dr. Robert Kern M.D.||Chief Medical Officer||N/A||N/A||N/A|
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Lyra Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.